Advantages:
- Optimized Dosage Delivery
- Real-time Treatment Monitoring
- Personalized and Enhanced Treatment Plans
Summary:
The market demand for Yttrium-90 radioembolization (RE) has grown significantly over the past decade as a crucial transcatheter intraarterial therapy for patients with unresectable liver cancer. To enhance the effectiveness and safety of this therapy, there is a pressing need for advanced tools and insights into hepatic artery hemodynamics. This demand has given rise to the field of computational fluid dynamics (CFD) modeling applied to RE. CFD modeling provides a clinical perspective for optimizing RE by simulating the intricate fluid mechanics within the hepatic arteries. These simulations offer invaluable insights into the therapy's mechanisms and potential improvements. With a decade's worth of research, CFD models have become instrumental in advancing our understanding of hemodynamics during RE. Businesses can capitalize on this growing demand by offering cutting-edge CFD simulation solutions tailored to RE, helping healthcare professionals make informed treatment decisions. As technology evolves, the market for CFD simulations in RE is poised for expansion, and companies that can provide innovative solutions will find themselves at the forefront of this vital healthcare niche. The future holds promising opportunities for firms specializing in CFD modeling for RE, driving advancements in liver cancer treatment.
Figure 1: Dosimetry from microsphere distribution. The microsphere 3D distribution directly gives the activity distribution (left), which in turn is convolved with the dose kernel (middle) to compute the dose distribution (right).
Figure 2: Right lobe blood flow ratio variation with the vessel generation. The markers and error bars show the mean and standard error of the mean (SEM), respectively.
Desired Partnerships:
- License
- Sponsored Research
- Co-Development